Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415578 | 0.85 | MEN1 (0.36) | MEN1KMT2ACDK2NPSR1RAB9A | |
| SCHEMBL920828 | 0.78 | ADORA1 (0.44) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| Lithium Ion SCHEMBL23674274 | 0.75 | L3MBTL1 (0.41) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL5749751 | 0.75 | KDM4E (0.51) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL921576 | 0.75 | L3MBTL1 (0.54) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL3883249 | 0.71 | FFAR2 (0.48) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL27461233 | 0.71 | ADORA1 (0.43) | ADORA1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL124461 | 0.70 | GRM5 (0.47) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL13489802 | 0.70 | ADORA1 (0.48) | MEN1KMT2AADORA1CYP1A2CYP3A4 | |
| SCHEMBL23689528 | 0.69 | L3MBTL1 (0.43) | MEN1KMT2AADORA1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689394-A4 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2009-06-03 | — | — | EP | disclosed |
| US-7109220-B2 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-19 | — | — | US | disclosed |
| EP-1689394-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051387-A1 | AMINO SUBSTITUTED PYRIDINYL METHANONE COMPOUNDS USEFUL IN TREATING KINASE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-09 | — | — | WO | disclosed |
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | JANSSEN PHARMACEUTICA N. V. (BE) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124610-A1 | Amino substituted pyridinyl methanone compounds useful in treating kinase disorders | CDK6, CDK1, CDK3 | MEN1 1273/4885KMT2A 640/4885CDK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.